Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

PregLem initiates phase III clinical trial program for PGL-4001 in uterine myoma

Aug. 19, 2008

Dyax reports topline results from EDEMA4 phase III clinical trial of DX-88 in HAE

Aug. 19, 2008

Abbott and AstraZeneca enter nonexclusive U.S. marketing agreement for Crestor

Aug. 18, 2008

DiaMedica initiates enrollment in phase IIa clinical trial for DM-99 in type 2 diabetes

Aug. 18, 2008

New antidiabetic compounds described in recent patents

Aug. 18, 2008

CPEX signs manufacturing agreement for Nasulin with DPT Laboratories

Aug. 14, 2008

New agents for metabolic disorders described in recent patents

Aug. 13, 2008

SF-1019 approved in Malaysia

Aug. 13, 2008

Acrux and KV sign expanded agreement for Evamist and other products

Aug. 13, 2008

NeuroSearch reports positive results from TIPO-2 human metabolic study of tesofensine

Aug. 12, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...